Mylan launches generic Cleocin

PITTSBURGH — Mylan on Friday launched its generic of Cleocin (clindamycin palmitate hydrochloride) solution. The drug is indicated to treat serious infections caused by susceptible anaerobic bacteria and susceptible strains of streptococci, pneumococci and staphylococci when less toxic alternatives aren’t appropriate. 

 

The product had U.S. sales of about $30.9 billion for the 12 months ended March 31, according to IMS Health. Mylan’s generic will be available as a 75 mg/5 mL oral solution. 

 

Today’s launch is the fifth for Mylan in a week, having earlier launched generics of Vidaza injection and Rythmol capsules, as well as the first generics of Nuvigil and 50-mg Doryx.